TREATMENT WITH HUMAN MONOCLONAL ANTIBODY TO CONNECTIVE TISSUE GROWTH FACTOR (FG-

结缔组织生长因子 (FG-) 人单克隆抗体治疗

• 批准号: 7719299
• 负责人: HOWARD TRACHTMAN
• 金额: $ 0.64万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-22 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719299
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Hospitals; Hour; Infusion procedures; Institution; Patient observation; Patients; Pharmaceutical Preparations; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Visit; Week; connective tissue growth factor; human monoclonal antibodies; intravenous administration; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. FG-3019 treatment will be provided for 2 months and steady state PK will be conducted throughout the 2 month treatment period. The drug will be administered every 2 weeks for a total of 4 doses. FG-3019 will be administered as an intravenous infusion over 2 hours. The patient will remain in the hospital for 6 hours following the infusion for observation .The patient will be seen for a total of 6 visits over the 2 month treatment period.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 FG-3019将提供2个月的治疗，并在整个2个月的治疗期间进行稳态PK。该药物将每2周一次服用4剂。 FG-3019将在2小时内作为静脉输注。输注后，患者将在医院中呆6小时。在2个月的治疗期间，将观察该患者6次就诊。